20 likes | 244 Views
Journal : Cancer Immunology, Immunotherapy Article Title : Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting immunotherapy
E N D
Journal: Cancer Immunology, Immunotherapy Article Title: Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting immunotherapy Authors: Minh C. Nguyen, Guang Huan Tu, Kathryn E. Koprivnikar, Melissa Gonzalez-Edick, Karin U. Jooss and Thomas C. Harding Corresponding Author: Thomas C. Harding Ph.D, Five Prime Therapeutics, Inc., 1650 Owens Street Suite 200, San Francisco, CA 94158, (415) 365-5615 (Phone), (415) 365-5601 (Fax), tom.harding@fiveprime.com Electronic Supplemental Material 3: Supplemental Figure 1
ESM_3: Supplemental Figure 1. A B C Supplemental Figure 1: Comparison of protein microarray (ProtoArray) and ELISA based methods to detect Galectin-8, TARP and TRAP1 antibody responses in CRPC patients treated with GVAX immunotherapy for prostate cancer. Specific ELISAs were developed for determining galectin-8, TARP and TRAP1 serum autoantibodies. ELISA analysis of antigen specific pre- and post-treatment serum antibodies employing the 13 patients originally profiled by protein microarray analysis demonstrated comparability between the two assays.